TILS.L Regulatory News (TILS)

10 Jun 2008 10:12



10 June 2008 

Colostrinin™/CogniSure™ Sales Update - Estimated Market Value* $2.2m in First Half of 2008

ReGen Therapeutics Plc ('ReGen') announces that it is providing guidance on the market value of Colostrinin™/CogniSure™ ordered by Metagenics Inc., its licensee and distribution partner for the USA, Australasian and Canadian markets, in the first half of 2008. Based on the number of kilos ordered by Metagenics, and assuming all are sold, ReGen estimates that the market value of these orders would be approximately $2.2m

Percy Lomax, Executive Chairman of ReGen commented "We are delighted with the progress that Colostrinin™/CogniSure™ has made since its launch into the professional market. We believe this is a substantial achievement given that it is less than a year since the product was first launched in Australia and it has only been on the US market for eight months.

For further information, please contact:

Percy Lomax

ReGen Therapeutics Plc

Tel: 020 7153 4920

Roland Cornish/Felicity Geidt

Beaumont Cornish Limited

Tel: 020 7628 3396

David Scott/Nick Bealer

Alexander David

Tel: 020 7448 9800

Adrian Duffield/Jon Davies

College Hill Associates

Tel: 020 7457 2020

Note:

 *Market value is the total sales value at the price per unit paid by the consumer.